ATR - Company ID 0000896622
APTARGROUP, INC. trades as ATR and has a market capitalization of $8.01 B, making it the #1084 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.78B, up 5.4% from the prior year and net income of $392.79M. This page tracks APTARGROUP, INC. through 1,932 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years APTARGROUP, INC.'s revenue grew from $2.33B to $3.78B, a compound annual growth rate of 5.5%. Net profit margin expanded from 7.3% to 10.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider trade | 4 | 2026-05-21 |
| SD | - | 2026-05-18 |
| Major company event | 8-K | 2026-05-13 |
| Insider trade | 4 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-07 |
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
Aptar is a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, announced today that has been named one of America’s Climate Leaders by _USA Today_ for the fourth consecutive year.
_Use of Aptar Pharma’s UDS Powder system supports the development of a next‑generation, virus‑agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections_
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that Gael Touya, a seasoned global executive with more than 30 years of experience at the company, most recently as Aptar Pharma President, has been appointed President and Chief Executive Officer, effective September 1, 2026. He will succeed Stephan B. Tanda, who has served as President and Chief Executive Officer since 2017. Stephan is expected to continue to work closely with Gael and the Board as an advisor through the end of the year to help ensure a seamless transition as the company enters its next phase of growth. Stephan intends to retire from Aptar’s Board by the end of 2026 and the Board will appoint Gael as a director on September 1, 2026.
The largest companies sharing APTARGROUP, INC.'s SEC industry classification (plastics products, nec).
APTARGROUP, INC. (ATR) has a market capitalization of $8.01 B as of 2026-07-11, ranking #1084 among US-listed companies.
APTARGROUP, INC. reported revenue of $3.78B for fiscal year 2025, an increase of 5.4% year over year.
Yes. APTARGROUP, INC. reported net income of $392.79M in its latest fiscal year.